On January 21, 2021, the U.S. Food and Drug Administration (FDA) approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. This is the first FDA-approved injectable, complete regimen for HIV-infected adults.
The fact sheet, Preparing for Long-Acting Antiretroviral Treatment, presents information on this new treatment option, which is delivered monthly and generally in a clinical setting. These topics are covered in the fact sheet: Clinical; Delivery System: Healthcare Coverage; Procurement and Purchasing: Ryan White HIV/AIDS Program Assistance (access the 2019 HAB Program Letter, Long-acting Antiretroviral (ARV) Medication Guidance and Ryan White HIV/AIDS Program); as well as Cost-Sharing and Patient Assistance for the Uninsured (details coming soon from the manufacturer, ViiV Healthcare).
The fact sheet was prepared by the National Alliance of State and Territorial AIDS Directors (NASTAD), the HIV Medicine Association (HIVMA), and the American Academy of HIV Medicine (AAHIVM).
For Cabenuva prescribing information, clinical trials summaries, and teaching slide sets, see the HRSA-funded National HIV Curriculum's antiretroviral medications section.
Learn More About Long-Acting ART from the Ryan White HIV/AIDS Program
A session discussing Long-Acting ARV Treatment Regimens: Key Behavioral Considerations for Stakeholders, was convened at the Virtual 2020 National Ryan White Conference on HIV Care & Treatment. Featured speakers in the August 2020 session are HRSA's Glenn Clark and LCDR Emeka Egwim along with Tim Horn from NASTAD.
Additional clinical insights are summarized in the HIV.gov blog: Long-Acting Injectables Hold Promise for Maintaining Viral Suppression and Preventing HIV—Highlights from the Ryan White Clinical Conference (August 2020)